logo

RYTM

Rhythm·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --

RYTM fundamentals

Rhythm (RYTM) released its earnings on Nov 4, 2025: revenue was 51.30M (YoY +54.29%), beat estimates; EPS was -0.82 (YoY -12.33%), missed estimates.
Revenue / YoY
51.30M
+54.29%
EPS / YoY
-0.82
-12.33%
Report date
Nov 4, 2025
RYTM Earnings Call Summary for Q3,2025
  • Q3 Momentum: 10% global patient growth on IMCIVREE, $51.3M revenue, $416M cash runway
  • Upcoming Milestones: HO FDA PDUFA 12/20, PWS Phase II data Q1 2026, Japan NDA submission
  • Strategic Focus: MC4R pathway expansion into acquired obesity, international launches 2027
  • Operational Strength: 84% U.S. gross-to-net, disciplined R&D/S&G spend
EPS
Revenue

Revenue & Expenses

RYTM has released its 2025 Q3 earnings report, with revenue of 51.30M, reflecting a YoY change of 54.28%, and net profit of -52.90M, showing a YoY change of -21.23%. The Sankey diagram below clearly presents RYTM's revenue sources and cost distribution.

Key Indicators

Rhythm (RYTM) key financial stats and ratios, covering profitability, financial health, and leverage.
Rhythm (RYTM)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.
Trend
Breakdown
Rhythm (RYTM)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.
Trend
Breakdown
Rhythm (RYTM)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.
Trend
Breakdown
Where does Rhythm (RYTM) generate its revenue? Explore its key revenue streams and top earning regions.
By Business
Data source:
By Region
Data source:
Track Rhythm (RYTM) Dividend Yield, Payout Ratio & Sustainability Through Its Dividend History
Payout Ratio
Dividend Yield